Abstract:Major depressive disorder (MDD) is a debilitating illness characterized by neuroanatomical and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be precipitated by exposure to chronic stress. For decades, the monoaminergic deficit hypothesis of depression provided the conceptual framework to understand the pathophysiology of MDD. However, accumulating evidence suggests that MDD and chronic stress are associated with an imbalance of excitation-inhibition (E:I) within the PFC, generated by a deficit of inhibitory synaptic transmission onto principal glutamatergic neurons. MDD patients and chronically stressed animals show a reduction in GABA and GAD67 levels in the brain, decreased expression of GABAergic interneuron markers, and alterations in GABA<sub>A</sub> and GABA<sub>B</sub> receptor levels. Moreover, genetically modified animals with deletion of specific GABA receptors subunits or interneuron function show depressive-like behaviors. Here, we provide further evidence supporting the role of cortical GABAergic interneurons, mainly somatostatin- and parvalbumin-expressing cells, required for the optimal E:I balance in the PFC and discuss how the malfunction of these cells can result in depression-related behaviors. Finally, considering the relatively low efficacy of current available medications, we review new fast-acting pharmacological approaches that target the GABAergic system to treat MDD. We conclude that deficits in cortical inhibitory neurotransmission and interneuron function resulting from chronic stress exposure can compromise the integrity of neurocircuits and result in the development of MDD and other stress-related disorders. Drugs that can establish a new E:I balance in the PFC by targeting the glutamatergic and GABAergic systems show promising as fast-acting antidepressants and represent breakthrough strategies for the treatment of depression.

The glutamatergic system in the development of stress-induced depression

Targeting the dysfunction of glutamate receptors for the development of novel antidepressants

Microglial glutaminase 1 mediates chronic restraint stress-induced depression-like behaviors and synaptic damages

Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression

GluN2A: A Promising Target for Developing Novel Antidepressants

Stress induced microglial activation contributes to depression

Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments

A brief history of the development of antidepressant drugs: From monoamines to glutamate.

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

Dysfunction of Glutamatergic Synaptic Transmission in Depression: Focus on AMPA Receptor Trafficking

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

Ghrelin/GHSR System in Depressive Disorder: Pathologic Roles and Therapeutic Implications

From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders]

Targeting of NMDA Receptors in the Treatment of Major Depression.

Depression and the Glutamate/GABA-Glutamine Cycle

Microglia in depression: current perspectives

Sigma-1 receptor: A potential target for the development of antidepressants

Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions